Bioline Rx Ltd - ADR
BLRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.45M
Close$
$-2.35
170% downside
Current Fair Value
170% downsideOvervalued by 170% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $16.45 Million |
|---|---|
| Enterprise Value | $23.35 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.29 |
| Beta | 0.59 |
| Outstanding Shares | 4,351,357 |
Return
| Return on Equity | -42.99% |
|---|---|
| Return on Assets | -19.12% |
| Return on Invested Capital | 10.88% |
Valuation & Multiples
| P/E Ratio | -1.7 |
|---|---|
| PEG | - |
| Price to Sales | 1.12 |
| Price to Book Ratio | 0.67 |
| Enterprise Value to Revenue | 1.35 |
| Enterprise Value to EBIT | 7.46 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.43 |
| Debt to Equity | 0.56 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 27, 2026
EPS Estimate
$-1.04
Average shareholder expectationRevenue Estimate
$343,000
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
$428,500
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 103.45% |
|---|---|
| Total Calls | 10,200▼ 12.07% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.47%▼ 0.69% |
|---|---|
| Total Invested | $44,977▼ 66.84% |
| Investors Holding | 12▼ 3.00% |
ESG Score
No data
About Bioline Rx Ltd
CEO: Philip Serlin